Roberto Romero, MD
![](https://cme.inova.org/sites/default/files/styles/faculty_photo/public/faculty/2023-11/prb_chief_romero.jpg?itok=-WULA5iK)
Roberto Romero, MD, D.Med.Sci., is Chief of the Perinatology Research Branch and Director of the Division of Obstetrics and Maternal-Fetal Medicine of NICHD/NIH. He trained in Obstetrics and Gynecology and Maternal-Fetal Medicine at Yale University, where he was Director of Research, before joining NIH. Dr. Romero’s team has made seminal contributions to the diagnosis and treatment of ectopic pregnancy, prenatal diagnosis of congenital anomalies, prediction and prevention of preterm labor/delivery, and the role of infection/inflammation in preterm and term parturition. In addition, Dr. Romero is an author of over 1300 peer-reviewed publications and several books, including the medical best seller, Prenatal Diagnosis of Congenital Anomalies. He is an elected member of the National Academy of Medicine and the recipient of 18 Doctorate Honoris Causa and Honorary Professorships from Universities worldwide. Dr. Romero has been honored by national and international professional societies for his medical and scientific contributions, including the Ian Donald Gold Medal (International Society of Ultrasound in Obstetrics and Gynecology), the Erich Saling Award from the World Association of Perinatal Medicine, the Maternité Prize in Obstetrics, awarded by the European Association of Perinatal Medicine, and also, is the first obstetrician to receive the prestigious Asan Award in Medicine from the Asan Foundation in South Korea. According to Google Scholar, Dr. Romero's h-index is 187 and his work has been cited over 150,000 times. Dr. Romero is Editor-in-Chief for Obstetrics of the premier academic journal in the discipline, the American Journal of Obstetrics & Gynecology. The journal is over 150 years old, with a circulation of 41,000 in the United States, and has published work that has the changed the lives of mothers and children in the last century.
Financial relationships
-
Attribution:SelfType of financial relationship:PatentIneligible company:NiHTopic:biomarker for fetal death; rights assigned to NIHDate added:11/13/2023Date updated:11/13/2023